Research led by Penn Dental’s Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as a new oral delivery of two GLP-1 drugs previously approved by the FDA in injectable form.

Popular GLP-1 receptor agonist drugs for weight loss, also known as GLP-1 RAs, appear to be similarly effective among patients of different ages, races, and starting weights, with women benefiting somewhat more than men, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1…

Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide)…

Here’s a summary of the major announcements and trends from the 44th Annual JP Morgan Healthcare Conference in San Francisco (January 12–15, 2026) specifically in

JP Morgan 2026: Obesity & GLP-1 Therapies Take Center StageWhat the Latest Deals and Data Mean for the Future of Metabolic MedicineThe J.P. Morgan Healthcare

Here are the **highlights from Day 2 of the JP Morgan Healthcare Conference (San Francisco) specifically related to obesity, weight-gain therapies, and related drug developments

JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)1. Shift From “Weight Loss” to Chronic Metabolic DiseaseDay 3 discussions made it clear

Some people will get itching at the site of injection of the GLP-1 drugs. This is not common but is irritating. There are some things you can do to lessen the severity of the reaction.

President Trump’s plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular GLP-1 weight loss drugs.

A framework published by the European Association for the Study of Obesity (EASO) that addresses the pharmacological treatment of obesity and its complications. This framework proposes a new

Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.

The provided source explores the increasing use of GLP-1 receptor agonists like semaglutide and liraglutide in individuals with HIV. It highlights that these medications are beneficial for addressing obesity

A Washington Post article talks about the Trump administration experiment to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs like Ozempic, potentially benefiting millions of Americans

The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal

This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and

This patient-focused guide from JAMA Internal Medicine provides essential information for individuals utilizing GLP-1 medications for weight loss. It outlines the medications’ functions and offers practical dietary advice through a “MEAL” plan, emphasizing muscle

The practice of compounding pharmacies adding various supplements to GLP-1 receptor agonist formulations like semaglutide or tirzepatide is very common in the United States. These additions, which

“FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications.

A systematic review investigating the relationship between adiposity measures and the risk of developing colorectal cancer (CRC), building upon existing research that often relies solely on Body Mass

This source explores the impact of semaglutide, a weight loss medication, on muscle mass, glucose regulation, and bone health in adults with obesity. It highlights

This academic article presents a cost-effectiveness analysis of tirzepatide, a medication for managing overweight and obesity, comparing it against lifestyle modification (LSM) alone. Researchers used a simulation model to project lifetime health

A systematic review and meta-analysis of 85 prospective studies, examining the long-term impact of physical activity (PA) patterns throughout adulthood on mortality. The authors aimed to understand how consistent, increasing,

The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared

The provided text offers a comprehensive overview of how obesity has been understood and depicted across different historical periods, from ancient civilizations to the present day. It traces

This document presents a pilot feasibility study published in “Obesity Science & Practice” that investigates the effectiveness of an AI-driven Virtual Human (VH) intervention designed to enhance General Practitioner (GP)

This scholarly article from Aesthetic Surgery Journal Open Forum discusses the phenomenon of “Ozempic Face,” a term used to describe the accelerated facial aging and volume loss experienced by some patients

There is growing evidence—especially in the plastic surgery community—that the recent surge in GLP‑1 medications (like Ozempic, Wegovy, Mounjaro) for weight loss is fueling a

The provided text, originating from the Food and Drug Administration (FDA), serves as a crucial public health warning regarding counterfeit Ozempic (semaglutide) injections found within the U.S. drug

This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from

We ask experts for their views on the GLP-1 market in this exclusive eBook. GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to

Your Weight Matters Regional is traveling the country, bringing expert-led education and practical guidance to cities near you. These FREE half-day events are designed to